Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...
The preliminary results look promising for the Evolut for specific patients. The trial consists of mostly women, who have ...
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...
Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic annuli patients.
Medical Device Network on MSN15d
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.
Highlights,Evolut TAVR demonstrated significantly lower rates of bioprosthetic valve dysfunction (BVD) compared to SAPIEN at ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
The two-year results highlighted the continued superior performance of the Evolut TAVR valve in patients with a small aortic annulus. These results will be followed to assess long-term outcomes. MDT’s ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback